Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, Phase 1 neoadjuvant study of ELI-002 7P in combination with mFOLFIRINOX with or without an anti-PD1 checkpoint inhibitor in borderline and resectable pancreatic ductal adenocarcinoma (PDAC)

Next Previous
Trial Profile

A multicenter, Phase 1 neoadjuvant study of ELI-002 7P in combination with mFOLFIRINOX with or without an anti-PD1 checkpoint inhibitor in borderline and resectable pancreatic ductal adenocarcinoma (PDAC)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ELI 002 (Primary) ; Fluorouracil+Folinic acid+Irinotecan+Oxaliplatin
  • Indications Adenocarcinoma; Pancreatic ductal carcinoma
  • Focus Adverse reactions
  • Sponsors Elicio Therapeutics

Most Recent Events

  • 06 Nov 2025 New trial record
  • 29 Sep 2025 According to Elicio Therapeutics media release, The trial is expected to commence in first half of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top